Current development of mTOR inhibitors as anticancer agents

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Mammalian target of rapamycin (mTOR) is a key regulator of cellular metabolism, controlling the balance between catabolism and anabolism.
• mTOR signaling is frequently dysregulated in various cancers, making it a significant therapeutic target.
• Rapamycin and its derivatives represent established mTOR inhibitors with demonstrated anti-tumor activity.

Purpose of the Study:

• To review the clinical development of mTOR inhibitors as anticancer agents.
• To explore the future prospects of integrating mTOR inhibitors into combination cancer treatment strategies.

Main Methods:

• Review of clinical trial data for mTOR inhibitors.
• Analysis of existing literature on mTOR inhibitor efficacy and safety.
• Exploration of preclinical and clinical strategies for combination therapy.

Main Results:

• Early mTOR inhibitors, such as CCI-779, have shown objective tumor responses and improved survival in advanced renal cell carcinoma.
• Extensive clinical programs are evaluating mTOR inhibitors across diverse tumor types.
• mTOR inhibitors have demonstrated potential in achieving long-lasting tumor responses.

Conclusions:

• mTOR inhibitors are a validated class of anticancer agents with a significant clinical development history.
• Future strategies likely involve combining mTOR inhibitors with other targeted therapies or treatment modalities for enhanced efficacy.
• The role of mTOR inhibitors in cancer treatment is expanding, with ongoing research into their optimal application.